Abstract

Cohesin is best known as a multi-subunit protein complex that holds together replicated sister chromatids from S phase until G2. Cohesin also has an important role in the regulation of gene expression. We previously demonstrated that the cohesin complex positively regulates expression of the oncogene MYC. Cell proliferation driven by MYC contributes to many cancers, including breast cancer. The MYC oncogene is estrogen-responsive and a transcriptional target of estrogen receptor alpha (ERα). Estrogen-induced cohesin binding sites coincide with ERα binding at the MYC locus, raising the possibility that cohesin and ERα combine actions to regulate MYC transcription. The objective of this study was to investigate a putative role for cohesin in estrogen induction of MYC expression. We found that siRNA-targeted depletion of a cohesin subunit, RAD21, decreased MYC expression in ER-positive (MCF7 and T47D) and ER-negative (MDA-MB-231) breast cancer cell lines. In addition, RAD21 depletion blocked estradiol-mediated activation of MYC in ER-positive cell lines, and decreased ERα binding to estrogen response elements (EREs) upstream of MYC, without affecting total ERα levels. Treatment of MCF7 cells with estradiol caused enrichment of RAD21 binding at upstream enhancers and at the P2 promoter of MYC. Enriched binding at all sites, except the P2 promoter, was dependent on ERα. Since RAD21 depletion did not affect transcription driven by an exogenous reporter construct containing a naked ERE, chromatin-based mechanisms are likely to be involved in cohesin-dependent MYC transcription. This study demonstrates that ERα activation of MYC can be modulated by cohesin. Together, these results demonstrate a novel role for cohesin in estrogen-mediated regulation of MYC and the first evidence that cohesin plays a role in ERα binding.

Highlights

  • Over-expression of the MYC proto-oncogene is one of the most common oncogenic events in human cancers [1]

  • Because regulation of MYC by cohesin is conserved in several species [41,42,43,44,45], and MYC regulation is thought to be central to mechanisms of tumorigenesis in several types of cancer [27,28,29,30,31,32,33,34], it was of considerable interest to determine whether cohesinmediated regulation of MYC is relevant to human cancers

  • estrogen receptor alpha (ERa) and cohesin bind this site (ERE 1) in estrogen-stimulated MCF7 and T47D cells [50], and we found that RAD21 binds only when MCF7 or T47D cells are treated with estradiol

Read more

Summary

Introduction

Over-expression of the MYC proto-oncogene is one of the most common oncogenic events in human cancers [1]. MYC is a pleiotropic transcription factor that has been found to bind to 10– 15% of human genes [2,3,4]. MYC activation influences genes involved in multiple facets of tumor biology including proliferation [5,6,7,8,9], differentiation [10,11,12,13,14], apoptosis [15,16,17,18] and metastasis [19,20,21,22,23]. Recent studies demonstrate that MYC selectively binds to the promoter of active genes and amplifies their transcription [24,25]. Rather than changing which genes are expressed, high levels of MYC increase the transcriptional output of tumor cells [24]. MYC is located in the human chromosome 8q24 region, a 2 MB segment of chromosome 8 that contains susceptibility loci for several diseases including colorectal, ovarian, thyroid, prostate and breast cancer [27,28,29,30,31,32,33,34]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.